Journals / Mikrobiyoloji Bülteni / 2007 / Cilt: 41 - Sayı: 2

In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples

Klinik örneklerden izole edilen Candia glabrata suşlarının amfoterisin B, flukonazol ve itrakonazole in vitro duyarlılığının araştırılması

Pages
235–244
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results suggest that although C.glabrata strains that were isolated in our hospital were rarely resistant to fluconazole, resistance rate to itraconazole is relatively high.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In recent years, the incidence of Candida albicans infections tends to decrease, at least in some centers other Candida species have emerged as opportunistic pathogens.
📊
Key Findings & Data:In this study, the in vitro activities of amphotericin B, itraconazole and fluconazole were tested against 134 clinical C.glabrata strains.
💡
Conclusion & Impact:These results suggest that although C.glabrata strains that were isolated in our hospital were rarely resistant to fluconazole, resistance rate to itraconazole is relatively high.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:In vitro · Candida glabrata · İlaç direnci

Abstract

In recent years, the incidence of Candida albicans infections tends to decrease, at least in some centers other Candida species have emerged as opportunistic pathogens. Among non-albicans Candida species, C.glabrata is one of the most frequently isolated species. In this study, the in vitro activities of amphotericin B, itraconazole and fluconazole were tested against 134 clinical C.glabrata strains. The isolation and identification of the isolates were done by standard mycological methods.Microbroth susceptibility tests were done in accordance with CLSI microdilution method (M27A-2). MICs were read at both 24 and 48 hours. At 24'h", MIC range, MIC50 and MIC90 values for amphotericin B were 0.5-4 i-ig/ml, 2 |ag/ml and 4 |a.g/ml, respectively. At 48 h, MIC range, MIC50 and MIC90 values for amphotericin B were 2-4 |ag/ml, 4 |ag/ml and 4 |ag/ml respectively. At 24 h, 97% of the isolates were susceptible (S) and 3% were dose-dependent susceptible (S-DD) to fluconazole. None of the isolates were resistant (R) to fluconazole at this time point. At 48 h, 94% of the isolates were S, 5.2% were S-DD and 0.8% were R to fluconazole. At 24 h, 20.9% of the isolates were S, 73.1% were S-DD and 6% were R to itraconazole. At 48 h, 0.8% of the isolates were S, 62.7% were S-DD and 36.5% were R to itraconazole. These results suggest that although C.glabrata strains that were isolated in our hospital were rarely resistant to fluconazole, resistance rate to itraconazole is relatively high. Most of the isolates that are resistant to itraconazole remain susceptible to fluconazole.

Özet

Son yıllarda, Candida albicans'ın görülme sıklığı azalırken albicans dışı Candida türlerinin görülme sıklığında artış meydana gelmiştir. C.glabrata, albicans dışı Candida türleri içinde en sık saptanan türlerden biridir. C.glabrata'run çeşitli antifungal ilaçlar için saptanan duyarlılık oranları, diğer Candida türlerine göre farklı olup, antifungal direnç oranları diğer Candida türlerine göre daha yüksektir. Bu çalışmada, klinik örneklerden izole edilen 134 C.glabrata susunun amfoterisin B, flukonazol ve itrakonazole in vitro duyarlılık profili araştırılmıştır. Suşların izolasyonu ve tanımlanması standart mikolojik yöntemlerle gerçekleştirilmiş, antifungal duyarlılık testleri için CLSI (M27-A2) referans mikrodilüsyon yöntemi kullanılmıştır. C.glabrata suşlarının 24 saat inkübasyon sonunda amfoterisin B için MİK aralığı 0.5-4 u.g/ml, MİK50 2 u.g/ml, MİKg0 4 u.g/ml, 48 saat inkübasyon sonunda ise MİK aralığı 2-4 u.g/ml, MİK50 4 u.g/ml, MİKg0 4 u.g/ml olarak bulunmuştur. C.glabrata suşlarının, 24 saat inkübasyon sonunda, %97'sinin flukonazole duyarlı (S) ve %3'ün doza bağlı duyarlı (S-DD) olduğu saptanırken flukonazole dirençli (R) susa rastlanmamıştır. C.glabrata suşlarının 48 saat inkübasyon sonunda flukonazole %94'ünün S, %5.2'sinin S-DD ve %0.8'inin ise R olduğu saptanmıştır. Suşların, 24 saat inkübasyon sonunda %20.9'u itrakonazole S, %73.1'i S-DD ve %6'sı ise R, 48 saat inkübasyon sonunda ise %0.8'i itrakonazole S, %62.7'si S-DD ve %36.5'i ise R olarak bulunmuştur. Bu sonuçlar, hastanemizde izole edilen C.glabrata suşlarında flukonazol direncinin çok nadir, itrakonazole direncinin göreceli olarak daha yüksek olduğunu, itrakonazole dirençli suşların çoğunun ise flukonazole duyarlı olduğunu göstermektedir.

🔖

Cite This Article

AVCILAR, H., SANCAK, B., ARIKAN, S. (2007). In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples. Mikrobiyoloji Bülteni, Cilt: 41 - Sayı: 2, 235–244. https://ajindex.com/articles/298982

References (2)

  1. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-8. 2.Takakura S, Fujihara N, Saito T, Kudo T, linuma Y, Ichiyama S: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004; 53: 283-9. 3.Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003; 52: 71-7. 4.Pappas PG, Rex JH, Lee J, et al; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43. 5.Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C.albicans. Clin Microbiol Rev 1999; 12: 80-96. 6.Segal E, Elad D. Candida species and Blastoschizomyces capitatus, pp: 423-60.
  2. Collier L, Ballows A, Susman M (eds), Topley and Wilson's Microbiology and Microbial Infections. 1998, 9th ed. Oxford University Press, New York. 7.Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30: 19-24. 8.Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9. 9.Koç AN, Kocagöz S, Erdem F, Gündüz Z. Outbreak of nosocomial fungemia caused by Candida glabrata. Mycoses 2002; 45: 470-5. 10.Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-26. 11.Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol 20